相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Saturable Binding of Finasteride to Steroid 5 alpha-reductase as Determinant of Nonlinear Pharmacokinetics
Rie Suzuki et al.
DRUG METABOLISM AND PHARMACOKINETICS (2010)
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways
Andre N. Vis et al.
BJU INTERNATIONAL (2009)
Chemotherapeutic sensitization by endoplasmic reticulum stress
Yue Wu et al.
CANCER BIOLOGY & THERAPY (2009)
Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy
Mara P. Steinkamp et al.
CANCER RESEARCH (2009)
Pleiotropic Functional Properties of Androgen Receptor Mutants in Prostate Cancer
Jean-Pierre Bergerat et al.
HUMAN MUTATION (2009)
Prx1 Enhances Androgen Receptor Function in Prostate Cancer Cells by Increasing Receptor Affinity to Dihydrotestosterone
Rishi Raj Chhipa et al.
MOLECULAR CANCER RESEARCH (2009)
5α-Reductase inhibitor treatment of prostatic diseases: background and practical implications
J. Doersam et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2009)
Mechanisms mediating androgen receptor reactivation after castration
Xin Yuan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Androgen biosynthetic pathways in the human prostate
Van Luu-The et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates
Song Li et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Augmented suppression of androgen receptor signaling by a combination of α-tocopheryl succinate and methylseleninic acid
Haitao Zhang et al.
CANCER (2006)
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers
Yi Xu et al.
CLINICAL CANCER RESEARCH (2006)
Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period
MC Scholz et al.
JOURNAL OF UROLOGY (2006)
Enhancement of intermittent androgen ablation by off-cycle maintenance with finasteride in LNCaP prostate cancer xenograft model
SE Eggener et al.
PROSTATE (2006)
Androgen receptor in prostate cancer
CA Heinlein et al.
ENDOCRINE REVIEWS (2004)
Dutasteride, the dual 5α-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line
CB Lazier et al.
PROSTATE (2004)
The influence of finasteride on the development of prostate cancer
IM Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor
D Masiello et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
